Not advantageous in the treatment of patients with breast cancer and 10 or more positive lymph nodes compared to standard adjuvant chemotherapy.
Mortality in expert centers 1-2%.
Acute leukemia and myelodysplastic syndromes occur in 4-7% of treated patients.